Company Focus
Eli Lilly & Company
Latest Eli Lilly & Company News
Pharmaceutical
US e-commerce giant Amazon has begun dispensing weight-loss drugs to eligible Medicare patients for $50 a month, plugging its pharmacy arm into a federal program that has opened the US government's largest health coverage scheme to obesity medicines for the first time. 7 August 2026
Related News
Insights
Company Spotlight
A Danish clinical-stage TechBio company using its proprietary AI-Immunology platform to design therapeutic vaccines for cancer and infectious disease, with a pipeline spanning personalized, off-the-shelf, and bacterial vaccine candidates.
Latest News & Features of interest to Eli Lilly & Company
Biotechnology
US AI-native biotechnology company Aizen Therapeutics has announced a multi-program collaboration with a fellow San Diego-based, public biotech to design oral peptide therapeutics using its DaX foundation model. 18 August 2026
Biotechnology
US biopharma companies Fulcrum Therapeutics and Slate Medicines have agreed to combine in an all-stock merger, with the resulting entity operating as Slate Medicines, Inc. and trading on Nasdaq under the ticker "SLTE," the companies announced Monday. 17 August 2026
Biotechnology
Danish clinical-stage techbio Evaxion, which is developing novel vaccines with its pioneering AI-Immunology platform, is expanding its pipeline of cancer vaccine programs with EVX-05 against the deadly brain cancer glioblastoma. The company’s shares moved up 4.8% to $3.50 in pre-market activity on the news. 17 August 2026
Biotechnology
US biotech Biogen and its Chinese partner TJ Biopharma announced that felzartamab for injection - branded Jingfei in China - has been approved by China's National Medical Products Administration (NMPA) for use with lenalidomide and dexamethasone in adults with multiple myeloma who have received at least one prior line of therapy. 17 August 2026
Pharmaceutical
US pharma major Bristol Myers Squibb was hit with adverse developments on two separate legal fronts this month, both stemming from its 2019 acquisition of Celgene and its cardiovascular franchise. 17 August 2026
Biosimilars
Swiss affordable medicines company Sandoz today announced a major development, manufacturing and commercialization collaboration agreement with Shanghai Henlius Biotech, marking another significant step to broaden patient access to high-quality biosimilar medicines worldwide. 17 August 2026
Pharmaceutical
UK-based pharma major AstraZeneca and Hong Kong-headquartered biopharmaceutical firm Hutchmed say their SAFFRON Phase III trial has met both its primary and a key secondary goal, with Tagrisso (osimertinib) plus Orpathys (savolitinib) beating platinum-based doublet chemotherapy. 17 August 2026
Biotechnology
US biotech firm Capricor Therapeutics has won a reprieve for its Duchenne muscular dystrophy (DMD) cell therapy deramiocel, telling investors the FDA is prepared to consider an amended filing built around upper-limb muscle function rather than the cardiac claim rejected by an advisory panel last month. 17 August 2026
Pharmaceutical
UK pharma major AstraZeneca today revealed that it is discontinuing the eVOLVE-Lung02 Phase III trial evaluating volrustomig in combination with chemotherapy as a 1st-line therapy compared to pembrolizumab and chemotherapy in patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors express PD-L1 <50%. 17 August 2026
Biotechnology
US clinical-stage biotech Neumora Therapeutics on Friday announced that Joshua Pinto has been appointed as chief executive (CEO) and a member of the board of directors. 17 August 2026
Latest In Brief for Eli Lilly & Company
Pharmaceutical
Codis has agreed to acquire Catalent Pharma Solutions’ Nottingham, UK, facility, expanding its contract development and manufacturing organization (CDMO) capabilities in oral solid dose development and manufacturing. The deal is expected to close in the third quarter of 2026, subject to customary conditions. 7 July 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze